CO5280073A1 - Composiciones - Google Patents

Composiciones

Info

Publication number
CO5280073A1
CO5280073A1 CO01029583A CO01029583A CO5280073A1 CO 5280073 A1 CO5280073 A1 CO 5280073A1 CO 01029583 A CO01029583 A CO 01029583A CO 01029583 A CO01029583 A CO 01029583A CO 5280073 A1 CO5280073 A1 CO 5280073A1
Authority
CO
Colombia
Prior art keywords
released
minutes
phase
paracetamol
composition
Prior art date
Application number
CO01029583A
Other languages
English (en)
Inventor
Yue Chan Shing
James Grattan Timithy
Sengmanee Ken
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9890126&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5280073(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of CO5280073A1 publication Critical patent/CO5280073A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

1. - Una composición farmacéutica con una fase de liberación inmediata y una de liberación sostenida de paracetamol, comprendiendo la citada composición de 600 a 700 mg de paracetamol por dosis unitaria y un vehículo farmacéuticamente aceptable, caracterizada por tener un perfil de disolución in vitro (determinado por el dispositivo USP de tipo III, cesta de vaivén, con 250 ml de HCl 0,1 M a 37°C de temperatura, fijado a una velocidad de 15 carreras/min) con las siguientes limitaciones:de 30 a 48% liberado después de 15 minutosde 56 a 75% liberado después de 60 minutos>85% liberado después de 180 minutos.
CO01029583A 2000-04-19 2001-04-17 Composiciones CO5280073A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0009522.4A GB0009522D0 (en) 2000-04-19 2000-04-19 Composition

Publications (1)

Publication Number Publication Date
CO5280073A1 true CO5280073A1 (es) 2003-05-30

Family

ID=9890126

Family Applications (1)

Application Number Title Priority Date Filing Date
CO01029583A CO5280073A1 (es) 2000-04-19 2001-04-17 Composiciones

Country Status (25)

Country Link
US (2) US7943170B2 (es)
EP (1) EP1274402B1 (es)
JP (1) JP2003531165A (es)
KR (1) KR100845660B1 (es)
CN (1) CN100335046C (es)
AT (1) ATE438388T1 (es)
AU (2) AU6021201A (es)
BR (1) BR0110129A (es)
CA (1) CA2406373C (es)
CO (1) CO5280073A1 (es)
CY (1) CY1109483T1 (es)
CZ (1) CZ303275B6 (es)
DE (1) DE60139462D1 (es)
DK (1) DK1274402T3 (es)
EA (1) EA006103B1 (es)
ES (1) ES2329971T3 (es)
GB (1) GB0009522D0 (es)
HK (1) HK1053601A1 (es)
HU (1) HU230033B1 (es)
MX (1) MXPA02010347A (es)
NZ (1) NZ521799A (es)
TW (1) TWI282286B (es)
UA (1) UA76417C2 (es)
WO (1) WO2001080834A1 (es)
ZA (1) ZA200208084B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0009522D0 (en) * 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US20040186180A1 (en) * 2003-03-21 2004-09-23 Gelotte Cathy K. Non-steroidal anti-inflammatory drug dosing regimen
CN100348974C (zh) * 2003-09-30 2007-11-14 北京东方凯恩医药科技有限公司 一种药物组合物的检测方法
US20050095299A1 (en) * 2003-10-30 2005-05-05 Wynn David W. Controlled release analgesic suspensions
US8795723B2 (en) 2005-09-09 2014-08-05 Angelini Pharma Inc. Sustained drug release compositions
US20080057122A1 (en) * 2006-08-31 2008-03-06 Aaipharma Inc. Acetaminophen pharmaceutical compositions
MX336494B (es) * 2007-10-16 2016-01-21 Paladin Labs Inc Composicion de bicapas para la liberacion controlada de acetaminofeno y tramadol.
KR20100121463A (ko) 2007-12-17 2010-11-17 라보팜 인코포레이트 오용 예방적 방출 제어형 제제
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
AU2009223061B2 (en) 2008-03-11 2014-10-09 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
AU2009327312A1 (en) 2008-12-16 2011-08-04 Labopharm Europe Limited Misuse preventative, controlled release formulation
JP5726766B2 (ja) * 2009-02-13 2015-06-03 ロマーク ラボラトリーズ エル．シー． ニタゾキサニドの制御放出医薬配合物
BR112012004525A2 (pt) * 2009-08-31 2016-03-22 Depomed Inc composição farmacêuticas gástrico-rententivas para liberação imediata ou prolongada de acetaminofeno
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
CN103648486A (zh) * 2011-05-06 2014-03-19 葛兰素史密斯克莱有限责任公司 缓释对乙酰氨基酚制剂
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US20140206740A1 (en) * 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
US9629841B2 (en) * 2012-10-18 2017-04-25 Abbvie Inc. Formulations of pyrimidinedione derivative compounds
WO2016042570A1 (en) * 2014-09-16 2016-03-24 Suresh Pareek Extended release formulation of acetaminophen
IL295519A (en) 2016-03-09 2022-10-01 Nls 1 Pharma Ag Mazindol immediate-release/delayed-release multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2058562B (en) * 1979-09-14 1983-11-30 Beecham Group Ltd Pharmaceutical compositions containing paracetamol and ascorbic acid
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US4820522A (en) 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
EP0418596A3 (en) * 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
US5900425A (en) * 1995-05-02 1999-05-04 Bayer Aktiengesellschaft Pharmaceutical preparations having controlled release of active compound and processes for their preparation
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
BE1011045A3 (fr) * 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.
FR2766708B1 (fr) 1997-07-30 2000-05-05 Galenix Dev Composition contenant de l'hydroxypropylcellulose, de l'hydroxypropylmethylcellulose et/ou de l'ethylcellullose a titre d'agents desintegrants, et procede d'obtention
US5945123A (en) * 1998-04-02 1999-08-31 K-V Pharmaceutical Company Maximizing effectiveness of substances used to improve health and well being
US6126967A (en) 1998-09-03 2000-10-03 Ascent Pediatrics Extended release acetaminophen particles
US6254891B1 (en) 1998-09-03 2001-07-03 Ascent Pediatrics, Inc. Extended release acetaminophen
GB0009522D0 (en) * 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
US7897172B2 (en) * 2004-05-18 2011-03-01 L. Perrigo Company Tablets exhibiting reduced drug release variability

Also Published As

Publication number Publication date
EP1274402A1 (en) 2003-01-15
HU230033B1 (hu) 2015-05-28
GB0009522D0 (en) 2000-06-07
CN1426298A (zh) 2003-06-25
CA2406373C (en) 2010-06-29
CZ303275B6 (cs) 2012-07-11
KR20030009440A (ko) 2003-01-29
HK1053601A1 (en) 2003-10-31
CY1109483T1 (el) 2014-08-13
CA2406373A1 (en) 2001-11-01
ATE438388T1 (de) 2009-08-15
EA006103B1 (ru) 2005-08-25
US20110177168A1 (en) 2011-07-21
US7943170B2 (en) 2011-05-17
DE60139462D1 (de) 2009-09-17
HUP0300698A2 (hu) 2003-07-28
AU2001260212C1 (en) 2020-07-16
WO2001080834A1 (en) 2001-11-01
DK1274402T3 (da) 2009-11-16
ES2329971T3 (es) 2009-12-03
AU6021201A (en) 2001-11-07
CZ20023470A3 (cs) 2003-03-12
TWI282286B (en) 2007-06-11
MXPA02010347A (es) 2003-04-25
EP1274402B1 (en) 2009-08-05
NZ521799A (en) 2004-12-24
JP2003531165A (ja) 2003-10-21
UA76417C2 (en) 2006-08-15
EA200200954A1 (ru) 2003-04-24
KR100845660B1 (ko) 2008-07-10
ZA200208084B (en) 2003-10-08
PL358123A1 (en) 2004-08-09
BR0110129A (pt) 2002-12-31
US20040202716A1 (en) 2004-10-14
CN100335046C (zh) 2007-09-05
HUP0300698A3 (en) 2004-09-28
AU2001260212B2 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
CO5280073A1 (es) Composiciones
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
AR035927A1 (es) Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr
AR028299A1 (es) Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
ES2530719T3 (es) Formulaciones de oxicodona para ser administradas una vez al día
AR033688A1 (es) Composicion parenteral reconstituible
CO4940403A1 (es) Formulaciones de liberacion prolongada de derivados de eri- tromicina
WO2004012700A3 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
CL2009001899A1 (es) Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01).
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
NO20043871L (no) Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid
CO5160287A1 (es) Formulacion de liberacion controlada de divalproex sodico
AR006598A1 (es) "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
AR021806A1 (es) COMPOSICIoN FARMACÉUTICA EN FORMA DE TABLETA QUE COMPRENDE ENTACAPONA Y MÉTODO DE PREPARACIoN.
CO5650230A2 (es) Composiciones estables de atorvastatina preparadas con granulacion en humedo
CO5070569A1 (es) Compuesto de aminoazol o una sal farmaceuticamente aceptable del mismo y medicamento que los contienen
RU2002100058A (ru) Кристаллические производные 1-метилкарбапенема
CO4940406A1 (es) Composiciones de paracetamol de accion rapida
ECSP066318A (es) Composición para la liberación de una base debil por un periodo extendido de tiempo
CO6150128A2 (es) Formulacion de nevirapina de liberacion prolongada
AR036312A1 (es) Composicion farmaceutica
RU2007132971A (ru) Способы и материалы с транс-кломифеном для лечения мужского бесплодия
UY25798A1 (es) Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico.
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
AR032614A1 (es) Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina

Legal Events

Date Code Title Description
FC Application refused